CASI Pharmaceuticals (CASIF) Gains from Investment Securities (2020 - 2025)
CASI Pharmaceuticals (CASIF) reported Gains from Investment Securities of $1.8 million for Q4 2025, up 214.77% on a YoY basis from $572803.4 in Q4 2024, and up 8685.71% quarter-over-quarter from -$21000.0 in Q3 2025.
CASI Pharmaceuticals (CASIF) Gains from Investment Securities (2020 - 2025) Analysis & Trends
CASI Pharmaceuticals has reported Gains from Investment Securities for 6 years, with the latest figure at $1.8 million in Q4 2025.
- For the quarter ending Q4 2025, Gains from Investment Securities rose 214.77% year-over-year to $1.8 million; the trailing twelve-month figure through Dec 2025 stood at $322000.0 (down 92.71% YoY), and the FY2025 full-year result was $114814.0, down 94.2% from the prior year.
- Gains from Investment Securities for Q4 2025 stood at $1.8 million, up from -$21000.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $3.3 million in Q4 2021, with the low at -$1.6 million in Q4 2024.
- Historically, Gains from Investment Securities has averaged $433774.5 across 5 years, with a median of $10000.0 in 2023.
- The largest YoY upside for Gains from Investment Securities was 12410.0% in 2024 against a maximum downside of 154.64% in 2024.
- CASI Pharmaceuticals' Gains from Investment Securities stood at $3.3 million in 2021, then slumped by 101.38% to -$46000.0 in 2022, then soared by 6350.0% to $2.9 million in 2023, then plunged by 154.64% to -$1.6 million in 2024, then surged by 214.77% to $1.8 million in 2025.
- The last three Gains from Investment Securities figures came in at $1.8 million (Q4 2025), -$21000.0 (Q3 2025), and $111000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 860,679.92 Bn | 860,679.89 Bn | - |
| 2 | Belite Bio | 55,284.00 Bn | 55,284.00 Bn | - |
| 3 | Quantum Biopharma | 16,206.94 Bn | 16,206.93 Bn | - |
| 4 | Legend Biotech | 3,318.00 Bn | 3,317.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,543.84 Bn | 1,543.84 Bn | - |
| 6 | Evaxion A | 1,449.11 Bn | 1,449.09 Bn | - |
| 7 | Psyence Biomedical | 216.99 Bn | 216.98 Bn | - |
| 8 | Vertex Pharmaceuticals | 115.22 Bn | 107.97 Bn | 2.59 Bn |
| 9 | Abivax | 90.58 Bn | 90.58 Bn | - |
| 10 | CASI Pharmaceuticals | - | - | 3.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.80 Mn |
| Dec 31, 2025 | 1.80 Mn |
| Sep 30, 2025 | -21,000.00 |
| Sep 30, 2025 | -21,000.00 |
| Jun 30, 2025 | 111,000.00 |
| Jun 30, 2025 | 111,000.00 |
| Dec 31, 2024 | -1.57 Mn |
| Dec 31, 2024 | -1.57 Mn |
| Sep 30, 2024 | 1.25 Mn |
| Sep 30, 2024 | 1.25 Mn |
| Jun 30, 2024 | 1.86 Mn |
| Jun 30, 2024 | 1.86 Mn |
| Dec 31, 2023 | 2.88 Mn |
| Dec 31, 2023 | 2.88 Mn |
| Sep 30, 2023 | 10,000.00 |
| Sep 30, 2023 | 10,000.00 |
| Jun 30, 2023 | -938,000.00 |
| Jun 30, 2023 | -938,000.00 |
| Mar 31, 2023 | -140,000.00 |
| Mar 31, 2023 | -140,000.00 |